

PTO/SB/08 (07-05) Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

PADEMIN	Complete if Known	· · · · · · · · · · · · · · · · · · ·
Application Number	10/676,005	
Filing Date	October 2, 2003	
First Named Inventor	Norman L. Anderson	
Group Art Unit	1645	. •
Examiner Name	Hines, Jana A.	
Attorney Docket Number	ANDE-001/04US	

_	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/JH/	74.	2002/0037532 A1	03-28-2002	Regnier et al.		
1	75.	2005/0064422 A1	03-24-2005	Barnidge et al.		
	76.	2002/0123055 A1	09-05-2002	Estell et al.		
	77.	2002/0115056 A1	08-22-2002	Goodlett		
W	78.	2004/0229283 A1	11-18-2004	Gygi et al.		
	79.	60/334,325	11-29-2001	Lindall et al.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T²
	80.	WO 00/67017	11-09-2000	Chait et al.		
1111	81.	WO 01/86306	11-15-2001	Regnier et al.		
	82.	WO 06/128492	12-07-2006	Pratt et al.		
	83.	WO 04/013636	02-12-2004	Syngenta Participations AG		
	84.	WO 03/102220	12-11-2003	The Institute for Systems Biology		

	,	OTHER - NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No. 1		Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or count where published.	
/JH/	85.	BARR, J. R. et al., "Isotope Dilution-Mass Spectrometric Quantification of Specific Proteins: Model Application with Apolipoprotein A-I," Clinical Chemistry, 1996, pp. 1676-1682, Vol. 42(10).	
	86.	BERGEN, H. R. et al., "Online Single-Step Analysis of Blood Proteins: The Transferrin Story," Analytical Biochemistry, 2001, pp. 122-129, Vol. 296.	,
		CLARKE, N. J. et al., "Detection and Quantitation of Cellulary Derived Amyloid β Peptides by Immunoprecipitation-HPLC-MS," FEBS Letters, 1998, pp. 419-423, Vol. 430.	
	88.	GRIFFIN, T. J. et al., "Toward a High-Throughput Approach to Quantitative Proteomic Analysis: Expression-Dependent Protein Identification by Mass Spectrometry," J. Am. Soc. Mass Spectrom., 2001, pp. 1238-1246, Vol. 12.	
	89.	GYGI, S. P. et al., "Proteome Analysis of Low-Abundance Proteins Using Multidimensional Chromatography and Isotope-Coded Affinity Tags," Journal of Proteome Research, 2002, pp. 47-54, Vol. 1.	•
	90. GYGI, S. P. et al., "Quantitative Analysis of Complex Protein Mixtures using Isotope-Coded Affinity Tags," Nature Biotechnology, October 1999, pp. 994-999, Vol. 17.		
V	91.	GYGI, S. P. et al., "Mass Spectrometry and Proteomics," Current Opinion in Chemical Biology, 2000, pp. 489-494, Vol. 4.	

Examiner /Jana Hines/ (09/04/2007)	Date Considered	09/04/2007
------------------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Unique citation designation number (optional). See attached Kinds of U.S. Patent Documents. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Sub	estitute for form 1449A/PTO	Complete if Known		
		Application Number	10/676,005	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	October 2, 2003	
		First Named Inventor	Norman L. Anderson	
		Group Art Unit	1645	
(use as many sheets as necessary)		Examiner Name	Hines, Jana A.	
Sheet	2 of 3	Attorney Docket Number	ANDE-001/04US	

Examiner	Cite	OTHER - NON PATENT LITERATURE DOCUMENTS			
examiner Initials*	No. I magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
/JH/ ^{92.}		KALKUM, M. et al., "Detection of Secreted Peptides by Using Hypothesis-Driven Multistage Mass Spectrometry," PNAS, March 4, 2003, pp. 2795-2800, Vol. 100, No. 5.			
	93.	KIERNAN, U. A. et al., "High-Throughput Analysis of Human Plasma Proteins," American Biotechnology Laboratory, March 2002, pp. 26, 28.			
	94.	KIERNAN, U. A. et al., "High-Throughput Protein Characterization Using Mass Spectrometric Immunoassay," Analytical Biochemistry, 2002, pp. 49-56, Vol. 301.			
	95.	KIERNAN, U. A. et al., "Comparative Phenotypic Analyses of Human Plasma and Urinary Retinol Binding Protein Using Mass Spectrometric Immunoassay," Biochemical and Biophysical Research Communications, 2002, pp. 401-405, Vol. 297.			
	96.	KIPPEN, A. D. et al., "Development of an Isotope Dilution Assay for Precise Determination of Insulin, C-peptide, and Proinsulin Levels in Non-Diabetic and Type II Diabetic Individuals with Comparison to Immunoassay," The Journal of Biological Chemistry, May 9, 1997, pp. 12513-12522, Vol. 272, No. 19.			
	97.	KISELAR, J. G. et al., "Antigenic Surveillance of the Influenza Virus by Mass Spectrometry," Biochemistry, 1999, pp. 14185-14191, Vol. 38.			
	98.	KISELAR, J. G. et al., "Preservation and Detection of Specific Antibody-Peptide Complexes by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry," J. Am. Soc. Mass Spectrom., 2000, pp. 746-750, Vol. 11.			
	99.	MILLER, E. J. et al., "Quantitation of Type I, III, and V Collagens in Human Tissue Samples by High-Performance Liquid Chromatography of Selected Cyanogen Bromide Peptides," Analytical Biochemistry, 1991, pp. 54-60, Vol. 196.			
	100.	REGNIER, F. E. et al., "Comparative Proteomics Based on Stable Isotope Labeling and Affinity Selection," Journal of Mass Spectrometry, 2002, pp. 133-145, Vol. 37.			
	101.	STEMMANN, O. et al., "Dual Inhibition of Sister Chromatid Separation at Metaphase," Cell, December 14, 2001, pp. 715-726, Vol. 107.			
	102.	STEWART, I. I. et al., "18O Labeling: A Tool for Proteomics," Rapid Communications in Mass Spectrometry, 2001, pp. 2456-2465, Vol. 15.			
	103.	TUBBS, K. A. et al., "Detection and Quantification of β-2-Microglobulin Using Mass Spectrometric Immunoassay," Analytical Biochemistry, 2001, pp. 26-35, Vol. 289.			
	104.	VAN DEN AKKER, C. R. et al., "Recycling Immobilized Antibodies," Clinical Chemistry, 1981, pp. 1954-1955, Vol. 27, No. 11.			
	105.	Supplementary European Search Report dated January 9, 2007, 4 pages.			
	106.	"Quantitative Assay of Methionine Enkephalin and β -Endorphin in Pituitary," Foreign Medical Sciences Section on Pharmacy, June 1999, pp. 173-176, Vol. 26(3).			
	107.	"New Frontline in Research of Proteome: Quantitative Proteomics, "ACTA Biochimica et Biophysica Sinica, 2001, pp. 477, 479, Vol. 33(5).			
	108.	TANAKA, T. et al., "Secretory Production of Recombinant Human C-Reactive Protein in <i>Escherichia coli</i> , capable of binding with phosphorylcholine, and its characterization," Biochemical and Biophysical Research Communications, 2002, pp. 163-166, Vol. 295.			
V	109.	GRONBORG, M. et al., "A Mass Spectrometry-Based Proteomic Approach for Identification of Serine/Threonine-Phosphorylated Proteins by Enrichment with Phospho-Specific Antibodies," Molecular & Cellular Proteomics, 2002, pp. 517-527, Vol. 1.			

	-		
Examiner	/Jana Hines/ (09/04/2007)	Date	
Signature	10ana mnesi (03/04/2001)	Considered	09/04/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number (optional). ²See attached Kinds of U.S. Patent Documents. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

	•		
Sub	stitute for form 1449A/PTO	·	Complete if Known
		Application Number	10/676,005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	October 2, 2003
		First Named Inventor	Norman L. Anderson
		Group Art Unit	1645
	(use as many sheets as necessary)	Examiner Name	Hines, Jana A.
Sheet	3 of 3	Attorney Docket Number	ANDE-001/04US

		OTHER – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/JH/ 110.		IBARROLA, N. et al., "A Proteomic Approach for Quantitation of Phosphorylation Using Stable Isotope Labeling in Cell Culture," Analytical Chemistry, November 15, 2003, pp. 6043-6049, Vol. 75, No. 22.	
	111.	EVERLEY, P. A. et al., "Quantitative Cancer Proteomics: Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) as a Tool for Prostate Cancer Research," Molecular & Cellular Proteomics, July 2004, pp. 729-735, Vol. 3.	
	112.	MAYO, K. H., "Recent Advances in the Design and Construction of Synthetic Peptides: For the Love of Basics or Just for the Technology of It," TIBTECH, May 2000, pp. 212-217, Vol. 18.	
	113.	LAMLA, T. et al., "The Cell-Free Protein Biosynthesis – Applications and Analysis of the System," Acta Biochimica Polonica, 2001, pp. 453-465, Vol. 48, No. 2.	
	114.	ANDERSON, L., "Candidate-Based Proteomics in the Search for Biomarkers of Cardiovascular Disease," J. Physiol, 2005, pp. 23-60, Vol. 563.1.	
<u> </u>	115.	International Search Report for International Application No. PCT/US05/19932, mailed October 10, 2006, 5 pages.	
	116.	KUHN, E. et al., "Quantification of C-Reactive Protein in the Serum of Patients with Rheumatoid Arthritis Using Multiple Reaction Monitoring Mass Spectrometry and ¹³ C-Labeled Peptide Standards," Proteomics, 2004, pp. 1175-1186, Vol. 4.	
	117.	"Cyanogen Bromide and Formic Acid Peptide Mapping." Protocol from: Skopp, R. N. et al., "Fingerprinting of Proteins Cleaved in Solution by Cyanogen Bromide," Appl. and Theoret. Electrophoresis, 1989, pp. 61-64, Vol. 1.	
	118.	"Cardiovascular," Merriam-Webster Dictionary.	
1,	119.	"Human CRP Sequence in NCBI AAL-48218.	
V	120.	ONG, S. et al., "Properties of ¹³ C-Substituted Arginine in Stable Isotope Labeling by Amino Acids in Cell Structure (SILAC)," Journal of Proteome Research, 2003, pp. 173-181, Vol. 2.	
•			-,
	<u> </u>		
	<u> </u>		

Examiner	/Jana Hines/ (09/04/2007)	Date	
CAUTITION	73ana milesi (03/04/2007)	Date	I ∩9/∩4/2∩∩7
Cignotum		Considered	09/04/2007
Signature	<u></u>	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Unique citation designation number (optional). See attached Kinds of U.S. Patent Documents. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.